In a preclinical xenograft T-ALL model, Müller and colleagues recently demonstrated that co-targeting of CD47 and CD38 with anti-CD47 monoclonal antibodies plus daratumumab in combination significantly enhanced in vitro phagocytosis and prolonged survival as compared with single agent treatment [65]. The gene discussed is CD38; the disease is acute lymphoblastic leukemia.